Faced with an "AI mandate," many companies try to force-fit AI onto their current offerings, leading to failure. The correct first step is a fundamental assessment: is this problem even a good candidate for AI, or does the entire product need to be reimagined from the ground up?

Many pharma companies have breakthrough AI results in isolated functions, or "pockets of excellence." However, the ultimate competitive advantage will go to the company that first connects these disparate successes into a single, integrated, enterprise-wide AI capability, thereby creating compounded value across the organization.

Large pharma companies are discovering that implementing AI to solve one part of the drug development workflow, like target discovery, creates new bottlenecks downstream. The subsequent, non-optimized stages become overwhelmed, highlighting the need for a holistic, fully choreographed approach to AI adoption across the entire R&D pipeline.

The pharmaceutical industry risks repeating Kodak's failure of inventing but ignoring a disruptive technology. For Kodak, it was digital photography; for pharma, it's AI. The industry possesses vast amounts of data (the new 'film'), but the real danger lies in failing to embrace the AI-driven intelligence layer that can interpret and act on it.

Adding AI tools to current processes yields only incremental efficiency. To achieve significant business impact, leaders must rebuild their entire go-to-market system—roles, workflows, and data flow—with AI at the core, not as an add-on.

The technical and data preparation for an AI-driven healthcare world will take pharma companies 18-24 months. If they wait until AI tools are mainstream, they will face an insurmountable two-year gap to catch up, a period in which they will become irrelevant.

Long-term competitive advantage will belong not to firms with the best algorithms, but to those that build the most intelligent organizations *around* AI. The key is developing the ability to absorb, direct, and compound AI's power in service of coherent strategic goals.

Similar to how the rise of the internet forced every retail company to adopt e-commerce, the advancement of AI will mandate that every surviving pharmaceutical company becomes 'AI-native.' This isn't an optional upgrade but a fundamental business model shift necessary for survival in the coming years.

Pharma companies engaging in 'pilotitis'—running random, unscalable AI projects—are destined to fall behind. Sustainable competitive advantage comes from integrating AI across the entire value chain and connecting it to core business outcomes, not from isolated experiments.